In this study, EGF is the main biomarker for the treatment of BPH and is enriched in androgen response signaling pathways, suggesting that EGF may play a role in the treatment of BPH by regulating the expression of EGF and acting on the androgen signaling pathway. The gene discussed is EGF; the disease is benign prostatic hyperplasia.